SCHEMBL10345547

SCHEMBL10345547

CSC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCC(=O)OC(c3ccccc3)c3ccccc3)c3csc(N)n3)[C@H]2SC1.[Na+]

nearest known ligand 0.56

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG known ✓ P37231 1/20 0.54
▸ TDP1 Q9NUW8 9/20 0.56
▸ APEX1 P27695 4/20 0.56
▸ MAPT P10636 4/20 0.56
▸ HSD17B10 Q99714 4/20 0.56
▸ LMNA P02545 2/20 0.56
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ POLB P06746 2/20 0.56
▸ RECQL P46063 2/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ PKM P14618 1/20 0.56
▸ ABCC4 O15439 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ APAF1 O14727 2/20 0.54
▸ TSHR P16473 1/20 0.54
▸ PLCG1 P19174 1/20 0.54
▸ ABCC2 Q92887 1/20 0.54
▸ SIRT5 Q9NXA8 1/20 0.54
▸ NR1I2 O75469 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10345548 1.00 TDP1 (0.56) TDP1APEX1MAPTHSD17B10LMNA
SCHEMBL10643291 0.94 TDP1 (0.60) TDP1APEX1MAPTHSD17B10LMNA
SCHEMBL10644623 0.94 TDP1 (0.60) TDP1APEX1MAPTHSD17B10LMNA
SCHEMBL10345747 0.90 TDP1 (0.55) TDP1APEX1MAPTHSD17B10LMNA
SCHEMBL10345748 0.90 TDP1 (0.55) TDP1APEX1MAPTHSD17B10LMNA
SCHEMBL11282014 0.90 TDP1 (0.56) TDP1APEX1MAPTHSD17B10LMNA
SCHEMBL11285168 0.90 TDP1 (0.56) TDP1APEX1MAPTHSD17B10LMNA
SCHEMBL10643198 0.89 PTGS1 (0.54) TDP1APEX1MAPTHSD17B10LMNA
SCHEMBL10643194 0.89 PTGS1 (0.54) TDP1APEX1MAPTHSD17B10LMNA
SCHEMBL9482372 0.89 TDP1 (0.69) TDP1APEX1MAPTHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0191507-B1 NEW 2-OXYIMINO-3-OXOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARATION THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-05-16 — — EP disclosed
EP-0057422-B1 NEW CEPHEM COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-10-12 — — EP disclosed
EP-0191507-A2 New 2-oxyimino-3-oxobutyric acid derivatives and process for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-08-20 — — EP disclosed
US-4452851-A BACTERICIDES, ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-06-05 — — US disclosed
EP-0057422-A2 New cephem compounds, processes for preparation thereof and pharmaceutical composition containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-08-11 — — EP disclosed
Send feedback